Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951327 · ClinicalTrials.gov registry record
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
A clinical trial of Primary Sclerosing Cholangitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT00951327 is a study of Primary Sclerosing Cholangitis that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00951327, a study of Primary Sclerosing Cholangitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with primary sclerosing cholangitis (PSC) are affected by an inflammatory condition of the bile ducts. Unfortunately, patients with PSC have a 10 to 15 percent lifetime risk of developing gallbladder and bile duct cancers. Gallbladder and bile duct cancers have a five-year survival of only 5 to 10 percent. Surgery to provide a cure must remove all cancer confined to one area. In order to increase survival rates there is a need to identify cancer and pre-cancer early. This has been difficult to do. Patients who have lab tests, positive imaging tests or obstructions will usually have a test called ERCP (Endoscopic Retrograde Cholangiopancreatogram) to take biopsies and enlarge bile ducts or opening bile ducts with stents. Patients usually have cells in the bile ducts removed and analyzed, but there are not studies to show how sensitive this may be to determine if the cells are cancer or pre-cancerous. A new scope with a system using light filters called Narrow Band Imaging (NBI) may help detect cancer and pre-cancer more often and at an earlier stage.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951327
The ClinicalTrials.gov registry entry for NCT00951327 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (95% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 0 interventions.
NCT00951327 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00951327 about?
NCT00951327 is a clinical study titled "Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)". Patients with primary sclerosing cholangitis (PSC) are affected by an inflammatory condition of the bile ducts. Unfortunately, patients with PSC have a 10 to 15 percent lifetime risk of developing gallbladder and bile duct cancers. Gallbladder and bile duct cancers have a five-year survival of only ...
What is the current status of trial NCT00951327?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2008-11. Estimated completion is 2010-08.
What conditions does trial NCT00951327 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
Who is sponsoring clinical trial NCT00951327?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00951327 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
-
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
RECRUITING
-
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
RECRUITING · Early Phase 1
-
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.